Monday, August 17, 2009
Good News About Wine!
This is an Italian study, so surely no biases exist, right? Anyway, I am content to see a pro-wine study. heh heh I'll have to check the actual study data to find out if it matters if it is red or white wine.
Thursday, June 11, 2009
LBBC Teleconference Call: Breaking News from 2009 ASCO Meeting
Speaker:
Virginia Kaklamani, MD, DSc, of Northwestern University, provided an overview of the latest medical research and quality-of-life news reported at the 2009 meeting of the American Society of Clinical Oncology.
Dr. Kaklamani is an assistant professor of hematology/oncology at Northwestern University. She completed her fellowship in hematology/oncology in 2003 and received a Master of Science in clinical investigation from Northwestern University. Dr. Kaklamani has a certification from the American Board of Medical Oncology and her interests include breast cancer, cancer genetics, studying high risk families and the role of exercise and diet in breast cancer.
Lymph nodes
whether to do therapy directly on the lymph nodes or not
benefit to adding radiation to lymph node region if 1-3 positive nodes?
if larger tumor (2+ cm) and positive nodes, then some benefit to add radiation to axillary, if smaller tumor, not so beneficial.
Tamoxifen
metabolism of tamoxifen. It is the metabolized form that is the active drug. If can metabolize tamoxifen well, then it is very effective.
anti-depressants (Lexepro, Zoloft and commonly used antidepressants) may affect tamoxifen (endoxifene levels). For example, taking Zoloft reduces effectiveness. Lexepro does not interfere, so is fine to use.
Chemotherapy trials
Avastin
inhibits the blood vessels from forming. Avastin is an antibody that goes to the tumors and keeps them from growing. Allowed to use it with Taxol in breast cancer. The Ribbon 1 trial is looking at taxane and zolota to see how effective it is in combo with these. It showed that it is effective, no matter what the treatment using in combo.
Aromatese inhibitors
how they affect brain function - short term memory issues
large adjuvant trial looked at cognitive function between tamoxifen and letrozol. Letrozol did a little bit better than Tam. Study found that all participants had lower cognitive function than women of the same age
Diet, Exercise
Exercise
not a lot of data, not a lot of randomized trials -- but women who exercise do better. IT is a predictor of how women will do.
Diet
There doesn't seem to be a specific diet related to decreased breast cancer recurrence. Weight loss or at least weigh maintenance do better than women who either gain or lose weight. Weight more important than diet.
Supplements
no supplement has been foind to be helpful in protecting against or helping women with breast cancer
Vitamin D -- no difference found -- but when start measuring Vit D levels only 25% of patients are Vit D sufficient. 75% of us are Vit D deficient, therefore, we should encourage women to take supplement to maintain a healthy level of Vit D.
Ask doctor to measure Vit D level!
PARP Inhibitors
Help repair DNA -- if inhibit, it keeps DNA from being repaired -- in cancer cells this is good. For Triple Negative, there already is an issue with the repair mechanism of the cell, so if add a PARP inhibitor, the cell won't be able to survive and will die. Use PARP in Triple Negative and BRCA1/2+ carriers.
-Alaporit (oral PARP Inhibitor) -- gave only PARP Inhibitor (had had chemo before and didn't respond) 41% had response to PARP Inh. -- not much toxicity (fatigue, nausea only), so can be used effectively by itself.
-BSI201 (intravenous) -- looked at chemo with gemcitobine and carboplatin with and without PARP. By adding the PARP Inh. to the chem, respond rate increased hugely. 16% to 48%! Progression free survival increased, and significant improvement in overall survival. It is showing effectiveness in population that hasn't had many alternatives when standard treatment not working.
Tuesday, April 14, 2009
Excellent News about Triple Negative Breast Cancer
Friday, February 20, 2009
LBBC Teleconference: Understanding Lymphedema
- Removes useless waste
- thickens or thins the fluid
- detects the presence of any harmful microbes (bacteria)
- Could post-surgery MLD help the lymphatic system to recover from the shock of the procedure? Should MLD be required follow-up/treatment for the patient?
- Where can one find Low Level Laser Therapy practitioners, or to purchase a system for self-use?
- Is it really not recommended to have any massage therapy done? (Separate from MLD)
- Myofacial release -- could it be considered an alternative therapy since it helps to work the muscle and release shortening of muscle?
Tuesday, February 3, 2009
LBBC Understanding Treatment Options
Monday, January 26, 2009
Notes from LBBC Teleconference "Breaking News from 31st Annual San Antonio Breast Cancer Symposium"
- 4 Adria then 4 tax on 3 week cycle each (sequential arm) -- lower risk of recurrence of all
- 4 A + 4 T
- 4TAC
Another Punch to the Ovaries
Wednesday, January 21, 2009
Sunday, January 11, 2009
Non-invasive Targeted Radiofrequency Cancer Treatment
As I was watching the video and reading about the treatment, I couldn't help wondering whether this would be a better way to manage lymph nodes. Instead of blindly removing lymph nodes, the nanoparticles would cling to any infected nodes and the radio frequency would destroy only the cancer cells, leaving the healthy lymph nodes to continue functioning. I wish I could have had the opportunity to have that method used on me, rather than having the invasive removal of lymph nodes that resulted in lymphedema issues that I have to deal with for the next 50 years.
Saturday, January 10, 2009
Breastcancertrials.org
For example (unfortunately, this one is in Stanford, CA and not accessible to me):
Lymphedema Prevention and Detection
To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-Risk Status
Purpose
The purpose of this research study is to detect patients who might be at increased risk for the development of arm lymphedema based upon repeated non-invasive examination of the arms. When preventive interventions are appropriate, this study will compare the effectiveness of the usual treatments of massage and elastic sleeves with a new device, Flexitouch, which electronically simulates the effect of massage upon lymph flow.
Study groups
All participants will be monitored for evidence of early impairment in lymphatic function. Prior to surgery and once every 3 months after surgery, arm volume measurements and bioelectric impedance analysis (BIA) will be performed.
If a significant increase in BIA occurs, participants will be randomly assigned to 1 of 3 preventive treatment groups:
- Standard Care: Self-administered lymphatic massage in addition to a standard compression sleeve
- Flexitouch: Use the Flexitouch device to stimulate the lymphatics in addition to a standard compression sleeve
- Continued Follow-Up: Continued monitoring of both arms
Additional procedures
If signs of lymphedema develop, a small punch biopsy of the skin will be taken. Blood samples for study purposes. Optional donation of breast tissue and skin from surgery.
Trial length
24 months
Post-trial follow-up
Regulary, up to 5 years
Sponsor
Other
More information on this clinical trial
Cancer.gov (PDQ®) [Oct 23, 2008] , Google Scholar, PubMed, BreastCancer.org/Lymphedema, Dr. Susan Love/LymphedemaSunday, December 14, 2008
Hope For Triple Negatives?
http://www.sciencedaily.com/releases/2008/12/081212141847.htm
And then go on and read this article to understand why it is so important to have something like that vaccine. And now that I am sufficiently freaking out, I will stop reading.
Saturday, December 13, 2008
News from San Antonio Breast Cancer Symposium 2008
(Be sure to check out all 3 Days of updates!)
Something to take note of: Zometa, a bisphosphonate that is used to prevent bone loss, has been found to have positive effects on preventing cancer-recurrence.
Article in the Washington Post (Dec. 11, 2008) also mentions benefit to pre-menopausal women:
"In June, doctors were stunned when a big study found that Zometa _ given to prevent bone loss caused by certain cancer treatments _ also greatly cut the risk that cancer would recur in women who developed the disease before menopause"
